Detection of oncogenic human papillomavirus impacts anal screening guidelines in men who have sex with men.
OBJECTIVE
It has been shown that testing for oncogenic human papillomavirus (HPV+) improves the sensitivity of cytologic diagnosis of atypical cells of undetermined significance in the cervix and anus, reducing the number of patients requiring colposcopy or high-resolution anoscopy. Some recommend that men who have sex with men with any abnormal cytology undergo high-resolution anoscopy. We endeavored to determine whether HPV testing could predict future high-grade dysplasia (high-grade squamous intraepithelial lesions) and modify screening internals.


METHODS
This investigation was conducted via a retrospective chart review of subjects with atypical cells of undetermined significance anal cytology, high-resolution anoscopy, and HPV testing. Records were abstracted for prior and subsequent screenings.


RESULTS
Four hundred men who have sex with men (285 HIV-) underwent 2224 screenings. Of 224 subjects monitored for >2 years, the hazard ratio for developing high-grade dysplasia was 77% less for men who have sex with men who never had oncogenic HPV (HPV-) vs those who stayed HPV+ (P < .013). The hazard ratio for high-grade dysplasia in those who were HPV- vs those who became HPV- was not different. Risk of high-grade dysplasia was 28% within 6 months of becoming HPV+. The 3-year high-grade dysplasia risk was 15% and 54% for HPV- vs HPV+ subjects (P = .0006). Frequency of high-grade dysplasia in subjects who remained HPV- with predominantly atypical cells of undetermined significance cytology for 1, 2, or 3 years was 2%, 0% and 0% and was 17%, 0%, and 0% in HIV+ subjects. Kaplan-Meier analysis for HIV- subjects with HPV- predominantly atypical cells of undetermined significance cytology for 1 year showed <5% incidence of high-grade dysplasia at 4 years.


CONCLUSIONS
Change in HPV status can predict the risk of high-grade dysplasia. Subjects with predominantly HPV- atypical cells of undetermined significance cytology for 2 years have a decreased risk of high-grade dysplasia. HPV testing when screening for anal dysplasia could alter screening parameters.
Goldstone
Stephen E
SE
Department of Surgery, The Mount Sinai School of Medicine, New York, New York, USA. segmd@prodigy.net
Moshier
Erin
E
D000328:Adult; D001003:Anal Canal / Q000473:pathology / Q000821:virology; D001005:Anus Neoplasms / Q000175:diagnosis* / Q000453:epidemiology / Q000821:virology; D003113:Colonoscopy; D005500:Follow-Up Studies; D006679:HIV Seropositivity; D018451:Homosexuality, Male; D006801:Humans; D015994:Incidence; D008297:Male; D008403:Mass Screening / Q000592:standards*; D027383:Papillomaviridae / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000821:virology; D017410:Practice Guidelines as Topic; D011230:Precancerous Conditions; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D014412:Tumor Virus Infections / Q000175:diagnosis* / Q000453:epidemiology / Q000821:virology; D014481:United States / Q000453:epidemiology